Clinical Trial Update: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for masitinib in patients with gastrointestinal stromal tumor resistant to imatinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Gastro Intestinal Stromal Tumor | Phase 2 | Status: COMPLETED